Search the Newsreel

IAMGOLD (IAG) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President, Business Development and Investor Relations - Graeme Jennings President and Chief Executive Officer - Renaud Adams Chief Financial Officer - Marthinus Theunissen Chief Operating Officer - Bruno …

Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M

Earnings Call Insights: Co-Diagnostics (CODX) Q2 2026 MANAGEMENT VIEW * Dwight Egan (Chairman, CEO & President) framed Q2 as “another important step in our transition from platform development toward commercialization,” emphasizing “advancing regulatory milestones, expanding our global commercial opportunities, enhancing our platform capabilities and …

Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity

Co-Diagnostics (CODX) reported significant losses and minimal revenue for Q2 2026, leading management to flag substantial doubt about its ability to continue as a going concern without additional capital. The company posted a net loss of $6.3 million for the quarter and $15.4 million …

Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings

CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet

Co-Diagnostics (CODX) shares surged by nearly 80% on Tuesday, extending a six-session rally that has seen the stock climb over 630%. This surge is attributed to the company's expanded efforts to develop a PCR test for the Bundibugyo strain of the Ebola virus, amidst …

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR

This article announces a manager's transaction at QIAGEN N.V. involving Eva Pisa, a member of the administrative or supervisory body. The transaction is a retroactive adjustment for a February 2026 net share settlement, withholding an additional 544 shares to cover related taxes, and is …

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $0.17 million and a net loss of $6.3 million. The company highlighted significant operational progress, including advancing manufacturing in Saudi Arabia, expanding commercial outreach in Europe and …

Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a …

KRSNAA: Revenue and profit rose, dividend declared, and warrants issued to promoters amid tax appeals

EKF Diagnostics Cancels 40,000 Shares in Targeted Buyback

Needham reiterates Buy on Lucid Diagnostics stock, $3 target

Needham has reiterated a Buy rating and a $3.00 price target for Lucid Diagnostics Inc (NASDAQ:LUCD), citing potential upside from its current stock price of $0.97. The firm anticipates increased revenue growth as the company gains coverage for its EsoGuard test, especially with a …

CSV Initiated Coverage by Oppenheimer -- Rating Outperform

Oppenheimer has initiated coverage on Carriage Services (CSV) with an Outperform rating and a $48.00 price target. GuruFocus indicates the stock is currently undervalued by 10.8% at $35.11, despite some financial strength concerns. The company operates in the personal services industry, providing funeral and …

Diageo Reshapes Its Portfolio: Can Core Brands Drive Growth?

Diageo plc DEO is reshaping its portfolio and investment priorities as it seeks to restore sustainable growth amid a challenging spirits backdrop. Management's strategy centers on building relevant brands within competitive category strategies, sharpening customer and channel execution, and creating a more agile operating …

Insurance Australia Group Earnings: Australian Retail Strength Offset by Weak New Zealand

Carriage Services (NYSE:CSV) Coverage Initiated at Oppenheimer

Oppenheimer has initiated coverage on Carriage Services (NYSE:CSV) with an "outperform" rating and a $48 price target, suggesting a 41.68% upside. This comes despite the company missing recent quarterly earnings and revenue expectations. Analyst sentiment for CSV is currently mixed, with a consensus "Hold" …

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

Lucid Diagnostics Inc. (LUCD) reported a wider-than-expected Q2 loss of $0.06 per share, missing the Zacks Consensus Estimate of a $0.04 loss, and its revenues of $1.47 million also fell short of estimates. The company has underperformed the S&P 500 year-to-date, and its shares …

Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip

Lucid Diagnostics (LUCD) reported a Q2 2026 revenue beat of $1.47 million, surpassing expectations by 2.8%, though shares slipped slightly. The company matched Wall Street forecasts with a loss of 6 cents per share, and its EsoGuard test volume remained within target. Management highlighted …

Lucid Diagnostics earnings matched, revenue topped estimates

Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M

* Lucid Diagnostics press release [https://seekingalpha.com/pr/20618076-lucid-diagnostics-provides-business-update-and-reports-second-quarter-2026-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q2 Non-GAAP EPS of -$0.06 misses by $0.01. * Revenue of $1.47M (+26.7% Y/Y) misses by $0.46M. * Processed 2,770 EsoGuard tests * Lucid had cash and cash equivalents of $33.4 million as of June 30, …

Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. …

Lucid Diagnostics Secures EsoGuard Policy Adopted by Health Plans

Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86

Quest Diagnostics (NYSE:DGX) has declared a quarterly dividend of $0.86 per share, payable on October 21st to shareholders of record on October 6th. This dividend represents an annualized payout of $3.44 and a 1.4% yield. The company has a strong dividend history, having increased …

BCAL Diagnostics Limited (ASX:BDX) Share Price Falls 5.08% as Stock Trades Within Daily Range

Atomo Diagnostics Limited (ASX:AT1) Share Price Remains Unchanged as Stock Trades Within Daily Range

Suraksha Diagnostic releases Q4FY26 earnings call audio for investor review

Suraksha Diagnostic Q4 Results: Earnings call audio released for FY26 review

Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside

Lucid Diagnostics Inc (LUCD) is scheduled to release its Q2 2026 earnings on August 13, 2026, with revenue estimates at $1.44 million and earnings at $-0.07 per share. Analysts' revenue estimates for the full year 2026 and 2027 have declined, as have earnings estimates …

Carriage Services (NYSE:CSV) Lowered to "Strong Sell" Rating by Zacks Research

Zacks Research has downgraded Carriage Services (NYSE:CSV) from "hold" to "strong sell," despite the broader analyst consensus remaining at "hold" with an average price target of $52. The downgrade follows Carriage Services missing its latest quarterly earnings expectations, with reported EPS of $0.78 against …

Insurance Australia Group (ASX:IAG) Shares Confront A Sharper Margin Squeeze

IAG (ASX:IAG) Sees Over 15M Shares in Trading Volume Surge Following FY26 Insurance Earnings Update

Carriage Services (NYSE:CSV) Sets New 52-Week Low - Here's Why

Carriage Services (NYSE:CSV) stock hit a new 52-week low of $33.33, trading near $33.88, following disappointing quarterly results that missed EPS and revenue expectations. Despite this, analysts maintain a "Moderate Buy" rating with a $52 target price, and the company continues to pay a …

Die Qiagen-Aktie steigt nach Q2-2026-Zahlen und stabiler Prognose

Insurance Australia Group Ltd (IAUGF) (FY 2026) Earnings Call Highlights: Strong Premium Growth ...

This article first appeared on GuruFocus. Premiums: Grew 7.6% to $18.4 billion, including a 10-month contribution from RACQ; underlying growth was around 2%. Underlying Insurance Profit: Up 2.3% to nearly $1.6 billion ($1.58 billion). Net Profit After Tax: Just over $1 billion. Final Dividend: …

Suraksha Diagnostic Q1 Results: Net profit rises to ₹18.6 crore, up from loss

Diageo slips Wednesday, underperforms market

Diageo PLC (DGE) shares dropped 1.93% on Wednesday, closing at £17.32, as the FTSE 100 Index also fell. The stock underperformed the broader market and is now 19.14% below its 52-week high of £21.42.

Suraksha Diagnostic consolidated net profit rises 38.40% in the June 2026 quarter